Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
The Journal of Clinical Endocrinology and Metabolism|August 31, 2006
The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomasDalia L Batista, Xun Zhang, Roger Gejman, et al.
Biochemistry|May 26, 2004
Estrogen receptor-independent catechol estrogen binding activity: protein binding studies in wild-type, Estrogen receptor-alpha KO, and aromatase KO mice tissuesBrian J Philips, Pete J Ansell, Leslie G Newton, et al.
The Journal of Rheumatology|June 7, 2007
Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot studyChristina Charles-Schoeman, Dinesh Khanna, Daniel E Furst, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 16, 2005
Apolipoprotein A-I mimetic peptidesMohamad Navab, G M Anantharamaiah, Srinivasa T Reddy, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1997
Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammationT Kirchner, D C Argentieri, A G Barbone, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 1999
N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenaseP J Connolly, S K Wetter, K N Beers, et al.
Annals of Medicine|July 16, 2005
The double jeopardy of HDLMohamad Navab, G M Ananthramaiah, Srinivasa T Reddy, et al.
The American Journal of Cardiology|August 16, 2005
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendationsMichael H Davidson, Kevin C Maki, Thomas A Pearson, et al.
Acta Oncologica (Stockholm, Sweden)|November 19, 2025
Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancerJair Bar, Mona H Cai, Yookyung Christy Choi, et al.
Investigational New Drugs|March 20, 2020
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRJames M Cleary, Emiliano Calvo, Victor Moreno, et al.
Pageof 17